I enjoyed the new intro article, especially the focus on solutions. Some nitpicks:
I’m not sure that it’s good to use 1DaySooner as the second example of positive EA interventions. I agree that challenge trials are good, but in my experience (admittedly a convenience sample), a lot of people I talk to are very wary of challenge trials. I worry that including it in an intro article could create needless controversy/turn people away.
I also think that some of the solutions in the biodefense section are too vague. For example, what exactly did the Johns Hopkins Center for Health Security do to qualify as important? It’s great that the Apollo Programme for Biodefense has billions in funding, but what are they doing with that money?
I don’t think it makes sense to include longtermism without explanation in the AI section. Right now it’s unexplained jargon. If I were to edit this, I’d replace that sentence with a quick reason why this huge effect on future generations matters or delete the sentence entirely.
I enjoyed the new intro article, especially the focus on solutions. Some nitpicks:
I’m not sure that it’s good to use 1DaySooner as the second example of positive EA interventions. I agree that challenge trials are good, but in my experience (admittedly a convenience sample), a lot of people I talk to are very wary of challenge trials. I worry that including it in an intro article could create needless controversy/turn people away.
I also think that some of the solutions in the biodefense section are too vague. For example, what exactly did the Johns Hopkins Center for Health Security do to qualify as important? It’s great that the Apollo Programme for Biodefense has billions in funding, but what are they doing with that money?
I don’t think it makes sense to include longtermism without explanation in the AI section. Right now it’s unexplained jargon. If I were to edit this, I’d replace that sentence with a quick reason why this huge effect on future generations matters or delete the sentence entirely.